AC Immune SA (NASDAQ:ACIU) has earned a consensus rating of “Hold” from the six brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.00.
Several equities research analysts recently issued reports on ACIU shares. BidaskClub lowered AC Immune from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. ValuEngine lowered AC Immune from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. Finally, Zacks Investment Research raised AC Immune from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Wednesday, February 6th.
A number of hedge funds and other institutional investors have recently modified their holdings of ACIU. BVF Inc. IL increased its position in AC Immune by 234.3% in the first quarter. BVF Inc. IL now owns 7,455,534 shares of the company’s stock worth $37,650,000 after buying an additional 5,225,507 shares during the period. Prosight Management LP acquired a new stake in AC Immune in the first quarter worth $3,588,000. BlackRock Inc. acquired a new stake in AC Immune in the fourth quarter worth $6,092,000. FMR LLC increased its position in AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock worth $53,039,000 after buying an additional 403,086 shares during the period. Finally, Artisan Partners Limited Partnership acquired a new stake in AC Immune in the first quarter worth $903,000. 26.54% of the stock is currently owned by hedge funds and other institutional investors.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Wednesday, May 15th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.36). The firm had revenue of $75.28 million for the quarter, compared to analyst estimates of $106.81 million. AC Immune had a net margin of 29.66% and a return on equity of 12.17%. On average, equities analysts expect that AC Immune will post 0.69 earnings per share for the current fiscal year.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Recommended Story: How are institutional investors different from individual investors?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.